PMID- 21709082
OWN - NLM
STAT- MEDLINE
DCOM- 20120109
LR  - 20211020
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Print)
IS  - 0066-4804 (Linking)
VI  - 55
IP  - 9
DP  - 2011 Sep
TI  - Daptomycin antibiotic lock therapy in a rat model of staphylococcal central 
      venous catheter biofilm infections.
PG  - 4081-9
LID - 10.1128/AAC.00147-11 [doi]
AB  - Antibiotic lock therapy (ALT) is an adjunctive procedure to prevent or treat 
      central venous catheter infections, ensuing catheter-related bacteremia, and 
      catheter-related metastatic infections. Daptomycin is a cyclic lipopeptide that 
      is rapidly bactericidal against methicillin-susceptible and -resistant 
      Staphylococcus aureus. The efficacies of daptomycin against central venous 
      catheter biofilms, catheter-related bacteremia, and catheter-related metastatic 
      infections were evaluated by adapting a previously reported central venous 
      catheter biofilm model in rats. Combined daptomycin ALT and systemic dosing 
      resulted in the clearance of an established in vivo S. aureus central venous 
      catheter biofilm after just two daily ALT treatments (30 min with daptomycin at 5 
      mg/ml) with concurrent systemic daptomycin dosing (40 mg/kg of body weight/day 
      subcutaneously [s.c.]; equivalent exposure of 6 mg/kg/day in people). Daptomycin 
      ALT solutions formulated in either saline or lactated Ringer's solution were 
      equally fast in eradicating established in vivo methicillin-resistant 
      Staphylococcus epidermidis (MRSE) central venous catheter biofilms. However, the 
      lactated Ringer's formulation was superior to that of saline in sustaining the 
      bacterial clearance of treated central venous catheters (83% versus 50%). In 
      MRSE-infected central venous catheter studies, 3 days of daptomycin or vancomycin 
      ALT (18 h at 5 mg/ml) with systemic s.c. dosing (40 mg/kg/day daptomycin or 100 
      mg/kg/day vancomycin) was equally effective 1 week posttherapy in maintaining 
      cleared central venous catheters (90% [n = 10] versus 100% [n = 8]). These 
      results suggest that daptomycin ALT, along with systemic dosing, could be an 
      effective treatment option for the prevention or eradication of staphylococcal 
      central venous catheter biofilm infections, thereby reducing the occurrence of 
      catheter-related bacteremia or catheter-related metastatic infections.
FAU - Van Praagh, Andrew D G
AU  - Van Praagh AD
AD  - Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421, USA.
FAU - Li, Tongchuan
AU  - Li T
FAU - Zhang, Shuxin
AU  - Zhang S
FAU - Arya, Anu
AU  - Arya A
FAU - Chen, Liping
AU  - Chen L
FAU - Zhang, Xi-Xian
AU  - Zhang XX
FAU - Bertolami, Shellie
AU  - Bertolami S
FAU - Mortin, Lawrence I
AU  - Mortin LI
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110627
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
RN  - 0 (Anti-Bacterial Agents)
RN  - 6Q205EH1VU (Vancomycin)
RN  - NWQ5N31VKK (Daptomycin)
SB  - IM
MH  - Animals
MH  - Anti-Bacterial Agents/*therapeutic use
MH  - Biofilms/*drug effects
MH  - Catheterization, Central Venous/*adverse effects
MH  - Daptomycin/*pharmacology
MH  - Methicillin-Resistant Staphylococcus aureus/drug effects/pathogenicity
MH  - Microbial Sensitivity Tests
MH  - Rats
MH  - Staphylococcal Infections/*drug therapy
MH  - Vancomycin/pharmacology
PMC - PMC3165291
EDAT- 2011/06/29 06:00
MHDA- 2012/01/10 06:00
PMCR- 2012/03/01
CRDT- 2011/06/29 06:00
PHST- 2011/06/29 06:00 [entrez]
PHST- 2011/06/29 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
PHST- 2012/03/01 00:00 [pmc-release]
AID - AAC.00147-11 [pii]
AID - 0147-11 [pii]
AID - 10.1128/AAC.00147-11 [doi]
PST - ppublish
SO  - Antimicrob Agents Chemother. 2011 Sep;55(9):4081-9. doi: 10.1128/AAC.00147-11. 
      Epub 2011 Jun 27.